These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 11149340)

  • 1. [Cost-effectiveness aspects of benign prostatic hyperplasia (BPH) therapy].
    Lopatkin NA; Ziborova IV; Sivkov AV; Apolikhin OI
    Urol Nefrol (Mosk); 1999; (1):22-6. PubMed ID: 11149340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Re: an economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia.
    DiSantostefano RL; Biddle AK; Lavelle JP
    Can J Urol; 2005 Feb; 12(1):2508-9; author reply 2509-10. PubMed ID: 15777487
    [No Abstract]   [Full Text] [Related]  

  • 3. An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia.
    McDonald H; Hux M; Brisson M; Bernard L; Nickel JC
    Can J Urol; 2004 Aug; 11(4):2327-40. PubMed ID: 15380054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BPH: costs and treatment outcomes.
    Nickel JC
    Am J Manag Care; 2006 Apr; 12(5 Suppl):S141-8. PubMed ID: 16613528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A trial of the use of finasteride and terazosin in patients with benign prostatic hyperplasia].
    Pushkar' DIu; Kosko DV; Loran OB; Kan IaD; Sapozhnikov IM; Tevlin KP
    Urol Nefrol (Mosk); 1995; (4):32-5. PubMed ID: 7571199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical management of benign prostatic hyperplasia--are two drugs better than one?
    Vaughan ED
    N Engl J Med; 2003 Dec; 349(25):2449-51. PubMed ID: 14681512
    [No Abstract]   [Full Text] [Related]  

  • 7. Finasteride in benign prostatic hyperplasia.
    Verhamme KM; Bosch RJ; Sturkenboom MC
    N Engl J Med; 2004 Mar; 350(13):1359-61; author reply 1359-61. PubMed ID: 15049034
    [No Abstract]   [Full Text] [Related]  

  • 8. [5-alpha reductase inhibitors or alpha blockers? The combination brakes best prostatic hyperplasia].
    MMW Fortschr Med; 2002 Oct; 144(44):56. PubMed ID: 12494605
    [No Abstract]   [Full Text] [Related]  

  • 9. An evaluation of the economic costs and patient-related consequences of treatments for benign prostatic hyperplasia.
    DiSantostefano RL; Biddle AK; Lavelle JP
    BJU Int; 2006 May; 97(5):1007-16. PubMed ID: 16542339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Finasteride to prevent morbidity from benign prostatic hyperplasia.
    Wasson JH
    N Engl J Med; 1998 Feb; 338(9):612-3. PubMed ID: 9475770
    [No Abstract]   [Full Text] [Related]  

  • 11. 5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery.
    Boyle P; Roehrborn C; Harkaway R; Logie J; de la Rosette J; Emberton M
    Eur Urol; 2004 May; 45(5):620-6; discussion 626-7. PubMed ID: 15082205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimising the medical management of benign prostatic hyperplasia.
    McDermott T
    Br J Clin Pract; 1997 Mar; 51(2):116-8. PubMed ID: 9158256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Drug treatment of benign prostatic hyperplasia].
    Schmid HP
    Praxis (Bern 1994); 1995 Sep; 84(39):1061-2. PubMed ID: 7481307
    [No Abstract]   [Full Text] [Related]  

  • 14. Urologic diseases in America project: benign prostatic hyperplasia.
    Wei JT; Calhoun E; Jacobsen SJ
    J Urol; 2005 Apr; 173(4):1256-61. PubMed ID: 15758764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of tamsulosin, doxazosin, and terazosin in the treatment of benign prostatic hyperplasia.
    Ohsfeldt RL; Kreder KJ; Klein RW; Chrischilles EA
    J Manag Care Pharm; 2004; 10(5):412-22. PubMed ID: 15369424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Drug therapy for benign prostatic syndrome (BPS)].
    Berges R
    Aktuelle Urol; 2006 Sep; 37(5):351-62. PubMed ID: 17004180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of benign prostatic hyperplasia. A pharmacoeconomic perspective.
    Eri LM; Tveter KJ
    Drugs Aging; 1997 Feb; 10(2):107-18. PubMed ID: 9061268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selecting therapy for maintaining sexual function in patients with benign prostatic hyperplasia.
    Nehra A
    BJU Int; 2005 Aug; 96(3):237-43. PubMed ID: 16042709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparative evaluation of the effectiveness and safety of combined drug therapy of patients with benign prostatic hyperplasia with finasteride and alfuzozine].
    Loran OB; Pushkar' DIu; Rasner PI
    Urologiia; 2002; (1):19-22. PubMed ID: 11877966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Benign prostatic hyperplasia: medical therapy].
    Schlenker B; Gratzke C; Weidlich P; Seitz M; Reich O; Stief CG
    MMW Fortschr Med; 2007 Aug; 149(33-34):29-31; quiz 32. PubMed ID: 17912863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.